SCHAUMBURG, Ill., Oct. 3 /PRNewswire-FirstCall/ -- Dauphin Technology, Inc. (“Dauphin”), a publicly traded company based in Schaumburg, Illinois, today announced that on September 28, 2006 it completed its merger with GeoVax, Inc., a privately held biotechnology company based in Atlanta, Georgia. Upon closing the merger, Dauphin’s name was changed to GeoVax Labs, Inc. and it was assigned a new CUSIP number: 373678101. The company’s common stock is now quoted on the NASDAQ OTCBB under the symbol DNTK.OB, and for a period of time will continue trading on the Pink Sheets under the symbol DNTK.PK. Further information, including a new stock symbol, shall be provided by GeoVax Labs, Inc.
Mr. Andrew J. Kandalepas, Dauphin’s former CEO and Chairman of the Board of Directors, stated, “On behalf of my Staff and Board of Directors, I thank all our shareholders for their continued loyalty, patience and support of our merger with GeoVax, Inc. I wish everyone ample success and prosperity in the future with the new company, GeoVax Labs.”
Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, changes in product demand, the availability of products, change in competition, economic conditions, various risks due to changes in market conditions and other risks detailed in the Company’s Securities and Exchange Commission filings and reports.
Dauphin Technology, Inc.
CONTACT: Andrew Kandalepas of Dauphin Technology, Inc., +1-847-303-6566
